… (CTCs) in men with mCRPC was associated with primary … prospectively enrolled patients
with mCRPC starting docetaxel or … AR-V7 in CTCs from men with mCRPC is not associated with …

Introduction Drug development and clinical decision making for patients with metastatic
prostate cancer (PC) have been hindered by a lack of quantitative methods of assessing …

… This end of the disease continuum is termed metastatic castration-resistant prostate cancer
(mCRPC), defined by cancer progression despite a testosterone level of <50 ng dl −1 (<1.7 …

… diphosphate[ADP]-ribose) polymerase inhibitor olaparib is combined with next-generation
hormonal agent abiraterone to treat metastatic castration-resistant prostate cancer (mCRPC). …

5000 Background: We previously reported that in men with mCRPC progressing after
docetaxel randomly assigned LuPSMA vs. cabazitaxel (Lancet 2021), those assigned LuPSMA …

… Prostate cancer is the second most common cause of cancer … In patients with metastatic
prostate cancer, androgen … metastatic castration-resistant prostate cancer (mCRPC) leading to …

… castration-resistant prostate cancer (mCRPC). There is now irrefutable evidence that the
AR axis is functional in most patients throughout the history of prostate cancer, is crucial from …

… (AR) and paracrine androgen biosynthesis in mCRPC may be more effective than either …
with AA in mCRPC Methods: We enrolled patients (pts) with progressive bone mCRPC, castrate …

… castration-resistant prostate cancer (mCRPC) in 2005 … among a growing list of agents for
mCRPC. A MEDLINE search was … of biomarkers to guide therapy for mCRPC is ideal, there are …

… First, men diagnosed with bone metastatic PC (mPC cohort), and second, a subset of
men with mPC fulfilling conditions for castration resistant prostate cancer (mCRPC cohort). …